Advertisement
U.S. markets closed
S&P Futures
4,566.75 -9.75 (-0.21%) Dow Futures
36,202.00 -66.00 (-0.18%) Nasdaq Futures
15,836.75 -32.25 (-0.20%) Russell 2000 Futures
1,880.20 -4.70 (-0.25%) Crude Oil
73.16 +0.12 (+0.16%) Gold
2,053.40 +11.20 (+0.55%)
Exact Sciences Corporation (EXAS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 67.03 |
| Open | 66.84 |
| Bid | 65.15 x 900 |
| Ask | 66.33 x 900 |
| Day's Range | 64.41 - 67.27 |
| 52 Week Range | 43.90 - 100.77 |
| Volume | |
| Avg. Volume | 1,458,895 |
| Market Cap | 11.875B |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.55 |
| Earnings Date | Feb 19, 2024 - Feb 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 92.69 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Exact Sciences CorporationAnalyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.RatingFair ValueEconomic Moat17 days agoMorningstar
ZacksExact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?
Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.
ZacksWhy Is Exact Sciences (EXAS) Up 2.5% Since Last Earnings Report?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insider MonkeyExact Sciences Corporation (EXAS) Shares Pulled Back in Q3
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned -7.98%, Advisor Class fund APDSX posted a return of -7.96%, and Institutional Class fund APHSX returned -7.97%, compared to a […]
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.